The Christie score for post-treatment response assessment PET/CT in patients with head and neck squamous cell carcinoma: a safe and simple scoring system.

Background: Radiotherapy with or without concurrent chemotherapy is a standard of care treatment for patients with head and neck squamous cell carcinoma (HNSCC). Upon completion, patients are referred for a post-treatment F-FDG PET/CT (Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) scan to help guide ongoing management by assessing for the presence or absence of residual or recurrent disease and differentiating this from post-treatment inflammation. To improve objective reporting of response, we developed the Christie score.

Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2-Stained Clinical Specimens in Breast Cancer.

Context.—: Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process due to the processing of clinical specimens by different laboratories and assessment by distinct pathologists.

Clinical and Epidemiological Information Required for Lyme Disease Surveillance in a Low-Incidence State, California 2011-2017.

Between January 1, 2011, and December 31, 2017, over 12,000 case reports of Lyme disease (LD) were submitted to the California Reportable Disease Information Exchange for further investigation. The number of case reports has tripled compared to previous years, emphasizing the need for efficient estimation and classification methods. We evaluated whether estimation procedures can be implemented in a low-incidence state such as California to correctly classify a case of LD, similar to those procedures used in high-incidence states.

Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems.

Despite its broad application in in vitro studies, the application of targeted protein degradation (TPD) to animal models faces considerable challenges. Here, we develop inducible and cell-type specific TPD systems in mice using two degron systems: Oryza sativa TIR1 (OsTIR1)-auxin-inducible degron 2 (AID2) and human cereblon (hCRBN)-SALL4 degron (S4D). Efficient degradation of Satb1 protein by these systems recapitulates phenotypes observed in the Satb1-deficient mice.

The 2009 FDA PRO guidance, Potential Type I error, Descriptive Statistics and Pragmatic estimation of the number of interviews for item elicitation.

A statistical methodology named "capture recapture", a Kaplan-Meier Summary Statistic, and an urn model framework are presented to describe the elicitation, then estimate both the number of interviews and the total number of items ("codes") that will be elicited during patient interviews, and present a summary graphical statistic that "saturation" has occurred. This methodology is developed to address a gap in the FDA 2009 PRO and 2012 PFDD guidance for determining the number of interviews (sample size). This estimate of the number of interviews (sample size) uses a two-step procedure.